Smythe Group

IMB brings home the GENE Awards

Published on: 17 November 2023

IMB won a third of the accolades at the Life Sciences Queensland GENE Awards

IMB spin-out announces successful clinical trial for psoriasis drug

Published on: 15 March 2023

The first oral treatment for psoriasis has a successful clinical trial

Deadly spider venom treatment for heart attacks reaches next milestone

Published on: 4 July 2022

A potentially life-saving treatment containing venom from one of the world’s deadliest spiders is one step closer to human trials, thanks to a $23 million investment in a Brisbane start-up.

Combinatorial chemistry and molecular design

The quest for drug discovery

Drug Discovery and Development

IMB spin-out company enters into $1B agreement with global pharmaceutical company

Published on: 30 May 2017

UQ IMB spinout company, Protagonist Therapeutics Inc., recently announced that it has initiated a Phase 1 clinical study and entered into a $1 billion worldwide agreement with a global pharmaceutical company.

NHMRC grant recipient Associate Professor Ben Hogan

$10M boost for IMB’s health and medical research

Published on: 5 December 2016

University of Queensland health and medical research projects aimed at improving the nation’s healthcare will benefit from more than $42 million in funding from the National Health and Medical Research Council for 2017.

UQ medical research recognised on national stage

Published on: 31 October 2016

Protagonist Therapeutics, a clinical-stage biopharmaceutical company founded on IMB research, has won Australian Company of the Year at the AusBiotech Industry Excellence Awards.

Biotech one step closer to bowel disease treatment

Published on: 22 August 2016

IMB spin-out biotech company Protagonist Therapeutics Inc is a step closer to developing a new drug that would benefit millions of people worldwide.